

Preprints are preliminary reports that have not undergone peer review. They should not be considered conclusive, used to inform clinical practice, or referenced by the media as validated information.

The risk of ocular adverse events after anti-PD-1/PD-L1 antibodies is dose-independent: a prospective observation report

Maho Sato (Satomahoq@gmail.com) Keiyu Hospital Hirohisa Kubono Keiyu Hospital Kazuya Yamashita Keiyu Hospital Takashi Nagamoto Keiyu Hospital Yoshiko Ofuji Keiyu Hospital Ryuki Fukumoto Keiyu Hospital Hideko Akagi Keiyu Hospital Mari Kawamura Keiyu Hospital Kotaro Suzuki Keiyu Hospital

Article

Keywords: Immune checkpoint inhibitor (ICI), immune-related adverse event (irAE), aqueous flare, central choroidal thickness (CCT)

Posted Date: September 8th, 2022

DOI: https://doi.org/10.21203/rs.3.rs-2013931/v1

License: (c) This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Abstract Background

Immune checkpoint inhibitors (ICIs) cause ICI-related adverse events (irAEs) such as dry eye and uveitis, sometimes necessitating the suspension of ICI treatment. To the best of my knowledge, this is the first prospective study on ocular irAEs. In this study, we aimed to identify early changes in ocular irAE and control conditions without suspending ICI treatment.

Methods

22 participants who began ICI treatment between July 2020 and July 2021 in Keiyu Hospital, Japan (3 women and 19 men; age, 69.1 ± 7.9 years, range, 53–83 years) were prospectively evaluated. The patients underwent ocular examinations before and 1, 3, and every 2 months after the initial dose of ICI. Examinations included measurement of aqueous flare and central choroidal thickness (CCT).

Results

Among the 22 participants, 6 developed systemic irAEs. Of these 6 patients, one experienced ocular pain after ICI treatment, likely due to dry eye disease. We did not observe any change in CCT or aqueous flare, even in patients with systemic AEs. This result suggests that ocular irAE is dose- independent, and we cannot predict whether the patient have risks of presenting irAE by following up ocular findings.

Conclusions

Ocular irAEs occur dose-independently.

Introduction

Immune checkpoint inhibitors (ICIs) are immunologic agents that prevent the growth of cancer cells by blocking inhibitory receptors, such as programmed death 1 (PD-1) and programmed death protein ligand 1 (PD-L1)¹². Ocular side effects secondary to ICIs are rare and reportedly occur in < 1% of patients, with dry eye and uveitis being the most frequent¹³. The characteristics of ocular side effects have gradually been recognized, and some cases of uveitis after ICI use resemble Vogt-Koyanagi-Harada disease (VKH)^{4–7}. Some cases have severe visual disturbance so that ICI treatment have to be halted. However, the frequency, timing of onset, and clinical characteristics have yet to be determined.

In previous reports about the prevalence of ocular immune checkpoint inhibitor-related adverse events (irAEs), ophthalmologic examinations were performed only when patients had ophthalmic complaints. Therefore, there is a possibility that only symptomatic changes were recognized as irAEs. As ICIs might be the only treatment left for some patients, it is ideal that irAEs can be predicted, identified early, and well controlled. This prospective study aimed to determine the clinical patterns of ocular irAEs, including slight and subclinical ocular changes, so that patients can continue cancer treatment without suspending ICI treatment.

Materials And Methods

Patients:

Recruited patients were those who began ICI treatment between July 2020 and July 2021 at Keiyu Hospital, Japan. The patients were referred to the ophthalmology department by their physician. The study protocol adhered to the tenets of the Declaration of Helsinki and was approved by the Institutional Ethics Committee (approval number R2-57). Written informed consent was obtained from every patient.

Eye examinations:

A total of 29 participants were recruited for this study. All patients underwent ocular examinations, including measurement of best-corrected visual acuity (BCVA) using a Landolt C chart, intraocular pressure (non-contact tonometer), fundus biomicroscopy, fundus photography, and spectral domain optical coherence tomography (OCT; Swept Source OCT, Triton, Topcon, Japan). OCT angiography and anterior segment OCT were done as well as fundus OCT.

Central choroidal thickness (CCT) was defined as the distance between the retinal pigment epithelium and the choroid–sclera boundary and was measured using the built-in scale of the OCT system. All measurements were recorded with reference to the scale bars in the OCT system. In the previous reports, CCT increases in VKH-like uveitis eyes as inflammation occurs in choroid⁷.

Aqueous flare was measured using an FM-600 laser flare meter (Kowa Co., Osaka, Japan). Seven consecutive flare readings with a background scatter of < 15% were acquired and averaged after excluding the minimum and maximum measurements. The results are presented as photon counts per millisecond (pc/ms). Increase in aqueous flare indicates inflammation in the anterior chamber.

Before ICI treatment, fundus biomicroscopy, fundus photography, OCT, and flare meters were performed with dilated pupils with tropicamide 0.5% and phenylephrine 0.5%. All recruited patients underwent systemic ophthalmologic examinations 1, 3, and every 2 months after the beginning of ICI treatment. Considering the physical condition of each patient, ophthalmologic examinations were performed with non-dilated pupils after the treatment began, if there was no subjective or objective change.

Statistical analysis:

Patient anonymity was maintained throughout the data collection and statistical analysis.

All data are expressed as the mean ± standard deviation. A comparative analysis between participants was performed using a paired t-test. Statistical significance was set at P < 0.05. The paired t-test was performed using Prism for Windows, version 9.1.0 (GraphPad Software, Inc., USA).

Results

Patients and clinical/ophthalmologic characteristics:

Of the 29 participants, 7 were excluded as they died before examination one month after the beginning of the treatment because of primary disease. This prospective study included 44 eyes of 22 participants (3 women and 19 men; mean age 69.1 ± 7.9 years; range, 53-83 years). They were followed up for more than one month after the beginning of ICI treatment. Among the 22 patients, 11 were followed up for 3 months after the initial treatment, 7 for 5 months, and 6 for 7 months. The study included 5 patients with a history of cataract surgery more than one year previously. None of the patients had a history of uveitis.

The primary cancers were located in the lungs (n = 8, 36.3%), stomach (n = 8, 36.3%), esophagus (n = 2, 9.1%), kidney (n = 2, 9.1%), pancreas (n = 1, 4.5%), and bladder (n = 1, 4.5%). ICIs included nivolumab (n = 15, 68.2%, with 2 patients also treated with ipilimumab), durvalumab (n = 3, 13.6%), pembrolizumab (n = 2, 9.1%), and atezolizumab (n = 2, 9.1%) (Table 2). The interval between each treatment was 2 weeks for nivolumab and durvalumab, and 3 weeks for pembrolizumab and atezolizumab.

The ophthalmic characteristics of the participants at the baseline are presented in Table 1. For the right and left eye, the respective mean axial length was 24.4 ± 1.1 mm and 24.4 ± 1.1 mm, mean spherical equivalent was -1.6 ± 2.5 and -1.9 ± 2.9 , and mean intraocular pressure was 13.7 ± 3.2 mmHg and 13.7 ± 2.4 mmHg.

The baseline CCT value for the right and left eye was $188.0 \pm 74.4 \mu m$ and 199.5 ± 75.0 respectively (Table 1). Respective aqueous flare values were 5.5 ± 2.2 pc/ms and 5.5 ± 2.5 pc/ms (Table 1).

Throughout the observation period, no participant reported visual disturbance. The mean aqueous flare and CCT showed no significant differences before and after the treatment (Table 3, Fig. 1). **Systemic irAEs:**

Six patients (#1 to #6) experienced systemic irAE. Patient #1 developed interstitial pneumonia after eight treatments with nivolumab and ipilimumab. ICI treatment was suspended and oral prednisolone was initiated. The patient complained of ocular pain in both eyes a few days after each treatment, which persisted even after oral prednisolone was initiated. The patient was diagnosed with dry eye disease prior to ICI treatment. The tear break-up time was 4 s in both eyes before and after ICI treatment, with slight superficial punctate keratopathy. There were no other objective changes in the ocular findings.

Patient #2 developed adrenocorticotropic hormone deficiency 3 months after the last dose of atezolizumab for stomach cancer. Atezolizumab was discontinued after three doses to evaluate progressive disease. Oral prednisolone was administered to the patient.

Patient #3 developed hypothyroidism and pituitary adrenal dysfunction after the second dose of nivolumab and ipilimumab for lung cancer. ICI was discontinued, and oral corticosteroids were started. Oral prednisolone was administered to the patient.

Patient #4 developed hypothyroidism after eight treatments with durvalumab. Levothyroxine was initiated, and durvalumab was continued. Ocular inflammation was not observed.

Patient #5 developed hypothyroidism, interstitial pneumonia, and sensory neuropathy after the third treatment with durvalumab. Oral prednisolone was administered to the patient. As lung cancer was judged as a progressive disease, durvalumab treatment was not continued. Ocular inflammation was not observed.

Patients #6 developed hypothyroidism after the first treatment with nivolumab. As the performance status deteriorated, nivolumab was discontinued. Ocular inflammation was not observed.

These six patients did not show significant changes in CCT and aqueous flare (Fig. 2a-d).

Discussion

By targeting patients with and without ocular symptoms, we aimed to identify subclinical ocular changes and clinical features of ocular irAEs. The prevalence of ocular irAE anti-PD-(L)1 treatment is reportedly < $1\%^{1}$, most frequently manifesting as uveitis (1%) and dry eye $(1-24\%)^{2}$. As most of the reported PD-1 inhibitor-related ocular complications occur within a few weeks to months after infusion², we performed a year follow-up.

None of the patients had visual impairments. One patient reported ocular pain after the ICI treatment. Patient #1 (Table 4) had dryness in both eyes before ICI treatment with a tear break-up time (BUT) of 4 seconds in both eyes with slight superficial punctuate keratopathy. The symptoms were worse for 2 weeks after every ICI treatment. The patient visited our clinic one week after the second ICI treatment, complaining of ocular pain in both eyes. BUT was also 4 second in both eyes with slight keratopathy at that time. We cannot conclude that the cause of ocular pain was deterioration of dry eye. However, the ICI treatment might have been influential in causing ocular pain. Including this patient as having dry eye as an ocular irAE, our result is consistent with the statistics (n = 1, 3.7%)².

No patient showed inflammatory change in both anterior or posterior segment. Exudative changes or retinal pigment epithelium rippling was not observed. We expected that choroidal thickness might increase in some patients after ICI treatment, as seen in VKH. However, the CCT did not show a significant change in our study.

Six participants experienced systemic irAEs. One of the patients (#1) complained of ocular pain. The other patients did not have ocular symptoms. Both CCT and aqueous flare did not show any significant differences before and after treatment in these six cases (Fig. 2).

In normal eyes, PD-L1 is detected in corneal epithelial cells, corneal endothelial cells, iris/ciliary body cells, and retinal pigment epithelial cells⁸. PD-L1 expressed on human ocular cells is thought to play a role in controlling ocular inflammation by inhibiting the production of proinflammatory and Th2 cytokines by activated T cells⁸. There is a possibility that ICI might collapse the immune control system at the blood-ocular barrier and increase the aqueous flare. This was not observed in this study (Table 3 and Fig. 1). However, several factors are related to aqueous flare measurements. Application of mydriatic agent⁹, pupil size¹⁰, and diurnal variation¹¹ of aqueous flares might have affected the test results. Aqueous flare intensity reportedly decreased significantly 1 h after the application of a mydriatic agent⁹. In the present study, we measured the flare intensity 30 min after the application of tropicamide 0.5% and phenylephrine 0.5%, which may have decreased the flare intensity. We did not dilate the pupil from the second visit, as the patients were undergoing chemotherapy and were not willing to undergo dilation. We understood the discomfort of having dilated pupils. Considering that the baseline was measured with a dilated pupil that decreases aqueous flare and that there were no significant differences in aqueous flare between the baseline and after ICI treatment, we can suggest that aqueous flare did not increase after ICI treatment.

Most of the reported PD-1 inhibitor-related ocular complications occurred within a few weeks to months after infusion², while there was no change in the ophthalmological findings in our observation.

The present study has several limitations. One is the small sample size. Inclusion of various types of cancer and ICIs is another. In addition, some participants died, which shortened the follow-up period. The timing of the ophthalmologic test after ICI treatment was one month after the treatment. However, this timing could have missed ocular changes that occurred just after the treatment.

We tested the participants without mydriasis after ICI treatment, considering the patients' conditions. However, matching the condition was needed to evaluate the differences in aqueous flare before and after ICI treatment.

Here, we described a one-year follow-up of the patients after ICI treatment. As long as we know, this is the first study to prospectively observe ophthalmologically. There was no patient who had ophthalmological change, which suggest that ophthalmological irAE is dose independent. Thus, we might be able to conclude from this study that we cannot predict whether the patient have risks of presenting irAE by following up ocular findings. However, this is still a study with small sample, so we are continuing this prospective study to validate the results of the present study using a larger sample size.

Declarations

Acknowledgement

The authors thank all the clinical staff members for their assistance with the data acquisition at the Department of Ophthalmology, Keiyu Hospital.

Disclosures

Financial Support: None

Conflicts of interest: The authors have no financial disclosures.

Authorship criteria: All authors attest that they meet the current ICMJE authorship criteria.

Ethics committee: Keiyu Hospital Institutional Ethics Committee (approval number R2-57)

Data availability

The datasets generated and analyzed during the current study are available from the corresponding author on request.

References

- 1. Antoun J, Titah C, Cochereau I. Ocular and orbital side-effects of checkpoint inhibitors: A review article. Curr Opin Oncol 2016;28:288–294.
- 2. Dalvin LA, Shields CL, Orloff M, et al. CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects. Retina 2018;38.
- 3. Abdel-Rahman O, Oweira H, Petrausch U, et al. Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev Anticancer Ther 2017;17:387–394. Available at: http://www.ncbi.nlm.nih.gov/pubmed/28277102.
- Obata S, Saishin Y, Teramura K, Ohji M. Vogt-Koyanagi-Harada Disease-Like Uveitis during Nivolumab (Anti-PD-1 Antibody) Treatment for Metastatic Cutaneous Malignant Melanoma. Case Rep Ophthalmol 2019;10:67–74.
- 5. Matsuo T, Yamasaki O. Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma. Clin Case Reports 2017;5:694–700.
- 6. Telfah M, Whittaker TJ, C. Doolittle G. Vision loss with pembrolizumab treatment: A report of two cases. J Oncol Pharm Pract 2019;25:1540–1546.
- 7. Bricout M, Petre A, Amini-Adle M, et al. Vogt-Koyanagi-Harada-like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma. J Immunother 2017;40:77–82.
- 8. Yang W, Li H, Chen PW, et al. PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation. Investig Ophthalmol Vis Sci 2009;50:273–280.
- 9. Oshika T, Kato S. Changes in aqueous flare and cells after mydriasis. Jpn J Ophthalmol 1989;33:271–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2796008.
- El-Harazi SM, Ruiz RS, Feldman RM, et al. Quantitative assessment of aqueous flare: the effect of age and pupillary dilation. Ophthalmic Surg Lasers 2002;33:379–82. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12358291.

11. Oshika T, Araie M, Masuda K. Diurnal variation of aqueous flare in normal human eyes measured with laser flare-cell meter. Jpn J Ophthalmol 1988;32:143–50. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2460653.

Tables

Table 1. Patients' characteristics

Age	69.1±7.9(53-83)					
Sex (male[%])	19[86.3]					
	right eye	left eye				
AL (mm)	$24.4~\pm~1.1$	24.4 ± 1.1				
SE (dioptor)	-1.6 ± 2.5	-1.9 ± 2.9				
IOP (mmHg)	13.7 ± 3.2	13.7 ± 2.4				
CRT (µm)	216.2 ± 30.6	222.9 ± 36.4				

Data are expressed as the mean ± standard deviation.

Table 2. Immune checkpoint inhibitors used

ICI	number of patients			
Nivolumab	13			
Nivolumab+Ipilimumab	2			
Pembrolizumab	2			
Durvalumab	3			
Atezolizumab	2			
total	22			

Number of patients for each ICI treatment is indicated.

Table 3. Comparisons of ocular findings between baseline and different timepoints

	base	1 month			3months			5months			7months							
	n=		n=22			n=11			n=7			n=6						
	right eye	left eye	right eye	pí@	left eye	p値	right eye	p慎	left eye	p值	right eye	p値	left eye	p傾	right eye	p值	left eye	p値
CCT (µm)	188.0 ± 74.4	199.5 ± 75.0	186.9 ± 0.8	0.99	195.8 ± 0.8	0.99	175.4 ± 67.8	0.99	194.1 ± 77.7	0.99	169.3 ± 60.1	0.97	182.0 ± 50.8	0.98	189.2 ± 54.9	>0.999	175.3 ± 39.2	0.94
flare(pc/ms)	5.5 ± 2.2	5.5 ± 2.5	8.9 ± 5.6	0.06	8.7 ± 5.1	0.08	6.8±2.6	0.97	8.42 ± 7.1	0.51	6.4 ± 3.4	0.99	7.2 ± 3.6	0.93	11.1 ± 11.1	0.15	6.3±3.0	0.99

Data are expressed as the mean ± standard deviation; Paired t-test.

CCT, central choroidal thickness

Table 4. Demographics, drug regimen, and cancer type of 6 patients with systemic irAEs

patient	age	gender	checkpoint inhibitor regimen	cancer diagnosis	systemic irAE	onset of systemic irAE	ocular irAE
#1	73	male	Nivolumab Ipilimumab	lung cancer	interstitional pneumonia	after 8th treatment	dry eye
#2	77	male	Atezolizumab	stomach cancer	ACTH deficiency	3 months after third(last) treatment	none
#3	62	male	Nivolumab Ipilimumab	lung cancer	hypothyroidismpituitary adrenal dysfunction	after second treatment	none
#4	74	male	Durvalumab	lung cancer	hypothyroidismpituitary	after 8th treatment	none
#5	62	male	Durvalumab	lung cancer	hypothyroidismpituitary interstitial pneumonia sensory neuropathy	after the third treatment	none
#6	66	female	Nivolumab	pancreas	hypothyroidismpituitary	after the initial treatment	none

Figures



Figure 1

Paired-samples t-test of 22 participants

a. Differences in flare between baseline and 1, 3, 5, and 7 months after initiation of treatment (right eye).b. Differences in flare between baseline and 1, 3, 5, and 7 months after initiation of treatment (left eye).c. Differences in CCT between baseline and 1, 3, 5, and 7 months after initiation of treatment (right eye).d. Differences in CCT between baseline and 1, 3, 5, and 7 months after initiation of treatment (left eye).



Figure 2

Paired-samples t-test of 6 participants with systemic irAEs

- a. Differences in flare between baseline and one month after treatment (right eye).
- b. Differences in flares between baseline and one month after treatment (left eye).
- c. Differences in CCT between baseline and one month after treatment (right eye).
- d. Differences in CCT between baseline and one month after treatment (left eye).